Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Frazier Life Sciences
Deal Size : $53.0 million
Deal Type : Series C Financing
35Pharma Closes Series C Funding for Activin Inhibitors in Pulmonary Diseases
Details : The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.
Brand Name : HS135
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 26, 2024
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Frazier Life Sciences
Deal Size : $53.0 million
Deal Type : Series C Financing
LOOKING FOR A SUPPLIER?